Guardant Health partners with Nuvalent for cancer diagnostics development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. BAC
4. DRS
5. GS
6. UNH
7. ORCL
8. AVAV
9. ACI
10. LMT

Go back to Guardant Health partners with Nuvalent for cancer diagnostics development

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infi

April 30, 2026 8:05 AM EDT

Multi-year global collaboration will leverage Guardants tissue and liquid biopsy portfolio to support clinical development and companion diagnostic strategies

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalents oncology pipeline using the tissue and liquid offerings of the Guardant... More